Walker Neal 4
4 · Aclaris Therapeutics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Walker Neal
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2026-01-02+29,150→ 1,508,974 total - Tax Payment
Common Stock
2026-01-02$2.88/sh−9,952$28,662→ 1,499,022 total - Exercise/Conversion
Restricted Stock Units
2026-01-02−29,150→ 30,034 total→ Common Stock (29,150 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.